目的：探讨转移抑制因子1（MTSS1）在胆管细胞癌组织中的表达及临床意义。方法：前瞻性收集2012年1月—2014年1月收治的89例胆管细胞癌患者作为研究组，同时收集因胆结石行胆囊切除的患者89例作为对照组。比较两组患者病理组织中MTSS1表达的差异，并进一步分析MTSS1与胆囊癌患者临床病理因素及预后的关系。结果：与对照组比较，研究组患者MTSS1阳性率明显降低（20.22% vs. 58.43%，P=0.000），MTSS1阳性细胞百分比显明降低（9.47% vs. 43.95%，P=0.000）。与MTSS1阳性的胆管细胞癌患者比较，MTSS1阴性者肿瘤大小明显增加（3.84 cm vs. 2.46 cm，P=0.000）、肿瘤分期为III或IV期的患者比例明显上升（70.42% vs. 27.78%，P=0.001）、淋巴结转移率明显增加（77.46% vs. 44.44%，P=0.028）、2年内病死率明显增高（42.25% vs. 16.67%，P=0.045）、肿瘤细胞为低分化者明显增加（P=0.001）。Logistic回归分析显示MTSS1阴性是胆管细胞癌患者死亡的独立危险因素（P=0.000），Wilcoxon检验显示MTSS1阳性患者生存率明显高于MTSS1阴性的患者（P=0.041）。结论：MTSS1表达下降或缺失与胆管细胞癌的发生和发展密切相关。
Expression of metastasis suppressor 1 in cholangiocarcinoma and its clinical significance
Objective: To investigate the expression of metastasis suppressor 1 (MTSS1) in cholangiocarcinoma tissues and its clinical significance. Methods: Eighty-nine patients with cholangiocarcinoma admitted from January 2012 to January 2014 were prospectively enrolled as study subjects, and meanwhile, 89 cases undergoing cholecystectomy due to cholecystolithiasis were collected as a control group. The difference in MTSS1 expression in the pathological tissues between the two groups of patients was compared, and the relations of MTSS1 expression with the clinicopathologic variables and prognosis of the patients with cholangiocarcinoma were analyzed. Results: Compared with control group, the positive rate of MTSS1 expression in study group was significantly decreased (20.22% vs. 58.43%, P=0.000), and the percentage of MTSS1 positive cells was also significantly reduced (9.47% vs. 43.95%, P=0.000). In patients with MTSS1 negative cholangiocarcinoma compared with those with MTSS1 positive cholangiocarcinoma, the tumor size was significantly increased (3.84 cm vs. 2.46 cm, P=0.000), the proportion of cases with clinical stage III or IV was significantly increased (70.42% vs. 27.78%, P=0.001), lymph node metastasis rate was significantly increased (77.46% vs. 44.44%, P=0.028), the 2-year mortality rate was significantly increased (42.25% vs. 16.67%, P=0.045) and the number of cases with low differentiated tumor cells was significantly increased (P=0.001). Logistic regression analysis showed that the loss of MTSS1 expression was an independent risk factor for death of patients with cholangiocarcinoma (P=0.000), and Wilcoxon test showed that the survival rate in patients with positive MTSS1 expression was significantly higher than that in patients with negative MTSS1 expression (P=0.041). Conclusion: The decrease or loss of MTSS1 expression is closely related to the occurrence and development of cholangiocarcinoma.